Analysts Say These Small Cap ASX Shares Could Rise 30% and 50%

The Motley FoolDec 1 21:02 ET

Paradigm Biopharmaceuticals Target Price Raised 70% to A$0.80/Share by Bell Potter>PAR.AU

Dow JonesDec 1 17:10 ET

Paradigm Biopharmaceuticals to Advance Knee Osteoarthritis Trial to Phase 3 Following US FDA Review

MT NewswiresNov 27 20:36 ET

Why Did This ASX Biotech Stock Explode 52% Higher on Monday?

The Motley FoolNov 25 01:21 ET

Paradigm Biopharmaceuticals Sees Stock Surge Amid Clinical Trials

TipRanksNov 24 23:52 ET

2 All Ords ASX Healthcare Shares Making BIG Moves on Quarterly Updates

The Motley FoolOct 30 21:39 ET